恩瑞格的服用说明

Iron overload increases the risk of infection, endocrine system damage, vital organ dysfunction, AML transformation in MDS patients, and shortens survival. Iron chelators are currently the mainstream treatment for iron removal. Among them, it is convenient to administer, significantly reduces ferritin levels, and has a definite effect in protecting important target organ systems such as the liver, heart, and endocrine system. It is currently the preferred option for iron removal treatment. Enreg is an oral iron chelator. Its primary use is to reduce chronic iron overload in patients receiving chronic transfusions for conditions such as beta-thalassemia and other chronic anemias. This is the first oral drug approved for this purpose in the United States. It was approved by the U.S. Food and Drug Administration (FDA) in November 2005. According to the FDA (May 2007), renal failure and cytopenias have been reported in patients receiving Enrigor oral suspension tablets. It is approved in the EU by the European Medicines Agency (EMA) for patients aged 6 years and older with chronic iron overload from repeated blood transfusions. 

Instructions for taking Enrig: Enrig dispersible tablets should be taken on an empty stomach at least 30 minutes before meals, once a day, preferably at the same time every day. Tablets should not be chewed or swallowed whole. Enrig dispersible tablets should not be taken together with aluminum-containing antacids, and the dosage (mg/kg) needs to be calculated and rounded to the nearest whole tablet. Completely dissolve the tablets in water, apple juice or orange juice (100-200mL) by stirring until a clear suspension is obtained and then drink it. The remaining medicine must be added with a small amount of water, apple juice or orange juice and mixed well before being taken. Not recommended for dissolution in carbonated drinks or milk as it can cause foaming and slow dispersion. At the same time, in order to ensure that the efficacy of Enriga is better exerted, combination with strong inducers of UDP-glucuronosyltransferase (UGT) (such as rifampicin, phenytoin, sedatives and hypnotics, protease inhibitors) and cholestyramine should be avoided. Do not administer concurrently with aluminum-containing antacids. Not to be combined with other iron chelation treatments. Be careful with repaglinide, drugs with potential ulcerogenic effects such as NSAIDs, cortisones, or oral bisphosphonates, drugs metabolized by CYP3A4 (such as cyclosporine, simvastatin, hormonal contraceptives). Pause at least 5 days before performing Gallium-67 imaging.